Skip to main content
. 2014 Oct 28;5:369. doi: 10.3389/fgene.2014.00369

Table 2.

Summary of main findings from rare variant reports in AD.

Study Design Population Sample size Variant/gene MAF % (EA/AA) OR (95% CI) P value
Cruchaga – PLD3
(Cruchaga et al., 2014)
Family based WES, genotyping, and targeted sequencing. EA (genotyping) 4998 cases, 6356 controls V232M/rs145999145 0.4884/0.2497 2.1 (1.47–2.99) 2.93 × 10-5
European (sequencing) 2363 cases, 2024 controls Gene based N/A 2.75 (2.05–3.68) 1.44 × 10-11
AA (sequencing) 130 cases, 172 controls Gene based N/A 5.48 (1.77–16.92) 1.4 × 10-3

Jonsson – APP (Jonsson et al., 2012) WGS, variants imputed in large cohort. Icelandic 71,743 chip genotyped individuals and 296,496 relatives A637T/rs63750847 0.0116/ 0.0 5.29 4.78 × 10-7

Kim – ADAM10 (Kim et al., 2009) Genotyping and targeted sequencing. EA 400 families (995 cases, 411 controls) rs2305421 Not in EVS 0.003
Gene based N/A 0.0043

Logue – AKAP9
(Logue et al., 2014)
Family based WGS, Genotyping. AA 1037 cases, 1869 controls rs144662445 0.0/0.4312 2.75 0.0022
rs149979685 0.0/0.3631 3.61 0.0022

Hunkapiller – UNC5C (Hunkapiller et al., 2013) Family based WGS and WES,
Genotyping.
EA 8050 cases, 98194 controls T835M/rs137875858 0.0581/0.0227 2.15 (1.21–3.84) 0.0095

Medway – APOE (Medway et al., 2014) EVS database,
Genotyping.
EA/ European 4128 cases, 4986 controls V236E/rs199768005 0.1188/0.0 0.1 (0.03–0.45) 7.5 × 10-5

Pottier – SORL1 (Pottier et al., 2012) WES in EOAD European origin 29 cases, 1500 controls 7/29 AD carried variants, no controls did

Summary of the study designs and major findings from the discussed rare variant association studies in the AD field. WGS, whole genome sequencing; WES, whole exome sequencing; EOAD, early onset Alzheimer’s disease; EA, European American; AA, African American; MAF, minor allele frequency. MAFs taken from NHLBI’s Exome Sequencing Project (EVS, Exome Variant Server; http://evs.gs.washington.edu/EVS/, accessed September 2014).